|
Dec 11
|
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
|
|
Dec 6
|
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
|
|
Nov 17
|
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
|
|
Aug 11
|
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
|